Quantifying pigment content in crustose coralline algae using hyperspectral imaging: A case study with Tethysphytum antarcticum (Ross Sea, Antarctica)
Journal of Phycology · 2024
DOI: 10.1111/jpy.13449 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Phycology, 2024. Verfasst von Juan C Montes-Herrera und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Marine and Antarctic Studies, College of Sciences and Engineering, University of Tasmania, Hobart, Tasmania, Australia. Hauptthemen laut MEDLINE: Rhodophyta, Phycobilins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Australian Research Council's Special Research Initiative for the Antarctic Gateway Partnership.
Abstract (Originalsprache)
Crustose coralline algae (CCA) are a highly diverse group of habitat‐forming, calcifying red macroalgae (Rhodophyta) with unique adaptations to diverse irradiance regimes. A distinctive CCA phenotype adaptation, which allows them to maximize photosynthetic performance in low light, is their content of a specific group of light‐harvesting pigments called phycobilins. In this study, we assessed the potential of noninvasive hyperspectral imaging (HSI) in the visible spectrum (400–800 nm) to describe the phenotypic variability in phycobilin content of an Antarctic coralline, Tethysphytum antarcticum (Hapalidiales), from two distinct locations. We validated our measurements with pigment extractions and spectrophotometry analysis, in addition to DNA barcoding using the psb A marker. Targeted spectral indices were developed and correlated with phycobilin content using linear mixed models ( R 2 = 0.64–0.7). Once applied to the HSI, the models revealed the distinct phycoerythrin spatial distribution in the two site‐specific CCA phenotypes, with thin and thick crusts, respectively. This study advances the capabilities of hyperspectral imaging as a tool to quantitatively study CCA pigmentation in relation to their phenotypic plasticity, which can be applied in laboratory studies and potentially in situ surveys using underwater hyperspectral imaging systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Marine and Antarctic Studies, College of Sciences and Engineering, University of Tasmania, Hobart, Tasmania, Australia.
- National Institute of Water and Atmospheric Research, Wellington, New Zealand.
- Tāmaki Paenga Hira Auckland Museum & School of Biological Sciences, University of Auckland, Auckland, New Zealand.
- School of Geography, Planning, and Spatial Sciences, College of Sciences and Engineering, University of Tasmania, Hobart, Tasmania, Australia.
ORCID-Profile: Juan C Montes-Herrera, Emiliano Cimoli, Vonda J Cummings, Roberta D'Archino, Wendy A Nelson, Arko Lucieer, Vanessa Lucieer
Förderung
- Australian Research Council's Special Research Initiative for the Antarctic Gateway Partnership
Zitieren
APA
Montes-Herrera, J. C., Cimoli, E., Cummings, V. J., D'Archino, R., Nelson, W. A., Lucieer, A., & Lucieer, V. (2024). Quantifying pigment content in crustose coralline algae using hyperspectral imaging: A case study with Tethysphytum antarcticum (Ross Sea, Antarctica). Journal of Phycology. https://doi.org/10.1111/jpy.13449
Vancouver
Montes-Herrera JC, Cimoli E, Cummings VJ, D'Archino R, Nelson WA, Lucieer A, et al. Quantifying pigment content in crustose coralline algae using hyperspectral imaging: A case study with Tethysphytum antarcticum (Ross Sea, Antarctica). Journal of Phycology. 2024. doi:10.1111/jpy.13449
BibTeX
@article{MontesHerrera2024,
author = {Montes-Herrera, Juan C and Cimoli, Emiliano and Cummings, Vonda J and D'Archino, Roberta and Nelson, Wendy A and Lucieer, Arko and Lucieer, Vanessa},
title = {Quantifying pigment content in crustose coralline algae using hyperspectral imaging: A case study with Tethysphytum antarcticum (Ross Sea, Antarctica)},
journal = {Journal of Phycology},
year = {2024},
doi = {10.1111/jpy.13449}
}
EUVIMED